253 related articles for article (PubMed ID: 22041526)
1. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
2. Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
Kobayashi M; Kubo S; Hirano Y; Kobayashi S; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):50-8. PubMed ID: 22036845
[TBL] [Abstract][Full Text] [Related]
3. ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.
Kobayashi M; Kubo S; Iwata M; Ohtsu Y; Takahashi K; Shimizu Y
Int Immunopharmacol; 2011 Jun; 11(6):732-9. PubMed ID: 21315169
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs.
Kubo S; Kobayashi M; Iwata M; Takahashi K; Miyata K; Shimizu Y
Eur J Pharmacol; 2011 May; 659(1):79-84. PubMed ID: 21385578
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
6. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
7. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation.
Kobayashi M; Kubo S; Shiraki K; Iwata M; Hirano Y; Ohtsu Y; Takahashi K; Shimizu Y
Pharmacology; 2012; 90(3-4):223-32. PubMed ID: 23038661
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
11. The role of phosphodiesterase 4B in IL-8/LTB4-induced human neutrophil chemotaxis evaluated with a phosphodiesterase 4B inhibitor.
Suzuki O; Goto T; Yoshino T; Nakamura S; Maeda H
Acta Pharm; 2015 Jun; 65(2):191-7. PubMed ID: 26011935
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.
Sanz MJ; Cortijo J; Taha MA; Cerdá-Nicolás M; Schatton E; Burgbacher B; Klar J; Tenor H; Schudt C; Issekutz AC; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2007 Oct; 152(4):481-92. PubMed ID: 17704822
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary inflammation in mice.
Xie YC; Dong XW; Wu XM; Yan XF; Xie QM
Int Immunopharmacol; 2009 Feb; 9(2):194-200. PubMed ID: 19071231
[TBL] [Abstract][Full Text] [Related]
14. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human.
Michel O; Dentener M; Cataldo D; Cantinieaux B; Vertongen F; Delvaux C; Murdoch RD
Pulm Pharmacol Ther; 2007; 20(6):676-83. PubMed ID: 17045826
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
18. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
19. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
[TBL] [Abstract][Full Text] [Related]
20. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.
Seehase S; Lauenstein HD; Schlumbohm C; Switalla S; Neuhaus V; Förster C; Fieguth HG; Pfennig O; Fuchs E; Kaup FJ; Bleyer M; Hohlfeld JM; Braun A; Sewald K; Knauf S
PLoS One; 2012; 7(8):e43709. PubMed ID: 22952743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]